August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Sakditad Saowapa: A Promising Targeted Option for Leptomeningeal Metastases from Solid Tumors
Aug 5, 2025, 17:18

Sakditad Saowapa: A Promising Targeted Option for Leptomeningeal Metastases from Solid Tumors

Sakditad Saowapa, Oncologist at UI Holden Comprehensive Cancer Center, shared a post on X:

“New Phase 2 TUXEDO‑3 trial (Nature Medicine, May 2025):

Patritumab deruxtecan (HER3‑DXd) given q3w to 20 patients with leptomeningeal metastases from solid tumors

  • 3‑mo survival: 65% (KM: 69.6%)
  • 6‑mo survival: ~59%
  • Most patients had stable or improved neuro symptoms and QoL
  • No new neuro AEs

Common AEs (any grade):

  • Anemia (41%), Nausea (32%),
  • Neutropenia (27%), Diarrhea (27%),
  • Asthenia (27%),  Headache / Thrombocytopenia (23%)

A promising targeted option in a devastating disease.”

Sakditad Saowapa

Title: Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial

Journal: Nature

Authors: Matthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera, María Gion, Richard Greil, Miriam Arumi, Manuel Ruiz-Borrego, Antonio Llombart-Cussac, María Valero, Javier Cortés, Marta Campolier, José Antonio Guerrero, Paula González-Alonso, Carlos Jiménez-Cortegana, Jose Rodríguez-Morató, Marta Vaz-Batista, Felicitas Oberndorfer, Maximilian Marhold, Anna Sophie Berghoff, Julia Furtner, Thorsten Fuereder, Rupert Bartsch

Read the full article.

Sakditad Saowapa

More posts featuring Sakditad Saowapa on OncoDaily.